Phase I/II Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
Phase of Trial: Phase I/II
Latest Information Update: 26 Oct 2017
At a glance
- Drugs GSK 2636771 (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 17 Jul 2017 Planned End Date changed from 1 Sep 2020 to 1 Jul 2020.
- 17 Jul 2017 Planned primary completion date changed from 1 Sep 2020 to 1 Jul 2020.
- 17 Jul 2017 Status changed from not yet recruiting to recruiting.